Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2027
Abstract: Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR‐CM) in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT). While ATTR‐ACT was not designed for a dose‐specific assessment, further analysis from ATTR‐ACT and its long‐term… read more here.
Keywords: attr act; attr; tafamidis transthyretin; transthyretin cardiomyopathy ... See more keywords
How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summary.
Sign Up to like & getrecommendations! Published in 2022 at "Future cardiology"
DOI: 10.2217/fca-2021-0150
Abstract: WHAT IS THIS PLAIN LANGUAGE SUMMARY ABOUT? This plain language summary describes some results of a study called ATTR-ACT. This was the first large study to include people with wild-type and hereditary transthyretin amyloid cardiomyopathy… read more here.
Keywords: attr; took placebo; placebo; heart ... See more keywords
Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language Summary.
Sign Up to like & getrecommendations! Published in 2023 at "Future cardiology"
DOI: 10.2217/fca-2022-0096
Abstract: WHAT IS THIS PLAIN LANGUAGE SUMMARY ABOUT? This summary presents the results from an ongoing, long-term extension study that followed an earlier study called ATTR-ACT. People who took part in this extension study and ATTR-ACT… read more here.
Keywords: long term; tafamidis; extension study; attr act ... See more keywords